Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACeD: KAN-101 in Celiac Disease
NCT04248855Phase 1Completed
- Sponsor
- Anokion
- Start
- Jan 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KAN-101 in celiac disease (7 cohorts), sponsored by Anokion. Primary endpoint: Incidence and Severity of Treatment-emergent Adverse Events at 28 days. Started Jan 2020; status: completed.
02
Drugs
KAN-101
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT04248855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248855.